Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilus
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-789
Abstract: Background: Luspatercept is an erythroid-maturation agent approved to treat anemia in patients (pts) with transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS) who are erythropoiesis-stimulating agent (ESA)–naive or –exposed. Luspatercept improved red blood cell (RBC) transfusion independence… read more here.
Keywords: pts treatment; approved dose; treatment; maximum approved ... See more keywords